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Background: This study examines the cost effectiveness of group follow-up after participation in the Dose
Adjustment for Normal Eating (DAFNE) structured education programme for type 1 diabetes.
Methods: Economic evaluation conducted alongside a cluster randomised controlled trial involving 437 adults with
type 1 diabetes in Ireland. Group follow-up involved two group education ‘booster’ sessions post-DAFNE. Individual
follow-up involved two standard one-to-one hospital clinic visits. Incremental costs, quality-adjusted life years
(QALYs) gained and cost effectiveness were estimated at 18 months. Uncertainty was explored using sensitivity
analysis and by estimating cost effectiveness acceptability curves.
Results: Group follow-up was associated with a mean reduction in QALYs gained of 0.04 per patient (P value, 0.052;
95% CI, −0.08 to 0.01, intra-class correlation (ICC), 0.033) and a mean reduction in total healthcare costs of €772
(P value, 0.020; 95% CI, −1,415 to −128: ICC, 0.016) per patient. At alternative threshold values of €5,000, €15,000,
€25,000, €35,000, and €45,000, the probability of group follow-up being cost effective was estimated to be 1.000,
0.762, 0.204, 0.078, and 0.033 respectively.
Conclusions: The results do not support implementation of group follow-up as the sole means of follow-up
post-DAFNE. Given the reported cost savings, future studies should explore the cost effectiveness of alternative
models of group care for diabetes.
Trial registration: Current Controlled Trials ISRCTN79759174 (assigned: 9 February 2007).
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The Dose Adjustment for Normal Eating (DAFNE)
programme, which comprises of group-based structured
education sessions, has become an established strategy
for enhancing self-management in individuals with type
1 diabetes [1]. The existing evidence base suggests that
the DAFNE programme is both cost saving and more
effective when compared with conventional treatment
[2,3]. This notwithstanding, questions remain as to how
follow-up care should be provided post-DAFNE in order
to maintain its benefits over the longer term. The Irish
DAFNE study sought to address this issue directly by* Correspondence: paddy.gillespie@nuigalway.ie
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reproduction in any medium, provided the orconducting a cluster randomised controlled trial (RCT)
to explore the clinical and cost effectiveness of group
follow-up versus individual follow-up after participation
in the DAFNE programme [4]. Notably, the study did
not evaluate DAFNE directly; rather it evaluated two
approaches to follow-up care post-DAFNE. This paper
reports the findings for the cost effectiveness analysis.
Full details of the trial methods are published elsewhere
[5]. In brief, a cluster RCT recruited six hospital clinics and
437 patients with a diagnosis of type 1 diabetes (Current
Controlled Trials ISRCTN79759174). Three clinics were
randomised to usual care, consisting of individual
follow-up, where participants (n = 221) were invited to
attend outpatient clinics at 6 and 12 months post-DAFNE
for one-to-one visits with a doctor, nurse and/or dietitian.
Three clinics were randomised to group follow-up, inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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DAFNE group and received “booster” education sessions
from programme educators at 6 and 12 months post-
DAFNE. A structured curriculum was developed to
facilitate the group follow-up sessions. This comprised
of a set of learning objectives across a range of topics
that were “offered” to participants on the basis of
their perceived need. Goal setting and action planning
was emphasised as was the reviewing of patients’ blood
sugar records (Table 1).
Details on the baseline characteristics of the participating
patients in each arm are presented in Table 2. Eighteen
patients in the intervention group and 23 patients in the
control group were lost to follow-up, leaving 398 (91%)
patients in the analysis. The primary outcome in the
clinical effectiveness analysis was change in glycated
haemoglobin (HbA1c) from baseline to follow-up. At
18 months, the trial showed no clinically or statisti-
cally significant difference in HbA1c between groups
(effect, 0.14; P value, 0.470; 95% CI, −0.33 to 0.61;
see Additional file 1: Table S1) [4]. The study concludes
that group follow-up was as effective as a one-to-one
individual clinic follow-up after structured education
for type 1 diabetes.
In addition to clinical effectiveness, any decision
regarding the adoption of a healthcare intervention
in clinical practice will depend upon its expected
cost effectiveness [6]. The technique of economic
evaluation explores cost effectiveness by relating the
mean difference in cost between alternative treatment
options to their mean difference in effectiveness, and
by quantifying the uncertainty surrounding these
incremental point estimates. This paper reports the
cost effectiveness results from an economic evalu-
ation conducted alongside the cluster RCT to com-
pare group follow-up versus individual follow-upTable 1 The Irish DAFNE Study: Describing the Intervention
DAFNE course The DAFNE course
who are using a ba
of structured educa
on carbohydrate es
The course is delive
regularly peer review
to the curriculum.
All groups are invite
skills learned and to
Group follow up Intervention arm pa
which they were as
Sessions were facilit
topics such as princ
hypoglycaemia. Gro
the curriculum to g
Participants were en




The economic evaluation was conducted following the
guidelines for health technology assessment for Ireland
[7]. It consisted of a trial-based analysis with a time
horizon of 18 months - the trial follow-up period.
Ethical approval for the study was provided by the
local committees at the participating study centres
(Galway University Hospitals; NUI Galway; Health
Service Executive Dublin Mid-Leinster; Beaumont
Hospital, Dublin; St Vincent's Healthcare Ethics and
Medical Research Committee, Dublin; Office for Research
Ethics Committee, Northern Ireland). Informed consent
was obtained from each participant. The perspective of
the healthcare provider was adopted with respect to
costing and health outcomes were expressed in terms
of quality-adjusted life years (QALYs). Data on resource
use and health status were collected via structured patient
questionnaires at baseline and at three follow-up points:
6 months, 12 months and 18 months. Given the length of
follow-up, neither costs nor outcomes were discounted.
The statistical analysis was conducted on an intention-
to-treat basis, and in accordance with current guidelines
for cluster RCTs [8-13]; that is, we adopt multilevel
statistical techniques which recognise both the clustering
and correlation in the cost and effect data. Descriptive
statistics, in the form of means, standard deviations and
intra-correlation (ICC) coefficients, were estimated for
the variables of interest. The incremental analysis was
undertaken using multivariate multilevel regression
techniques. Separate regression models were estimated
for costs and health outcomes, both of which were
estimated controlling for treatment arm, clustering, and ais delivered over 5 consecutive days to groups of up to 8 individuals
sal/bolus insulin regimen to manage their diabetes. It involves 38 hours
tion covering all aspects of diabetes self-management with an emphasis
timation and matching of quick-acting insulin to food.
red by a DAFNE-trained diabetes nurse, dietitian and doctor, who are
ed to ensure that the education is consistently delivered according
d back to a 3 hour review session at 6 weeks post-DAFNE to consolidate
review targets and goals.
rticipants met at 6 and 12 months post-DAFNE in the original group to
signed. Group follow-up sessions lasted approximately 3 hours.
ated by trained educators using a structured curriculum, which included
iples of insulin dose adjustment, carbohydrate estimation and managing
ups identified their own priorities for discussion while the educator used
uide the session.
couraged to reflect on progress and difficulties with their original
oals and to produce an updated action plan.
Table 2 Baseline characteristics of study participants by
treatment arm
Characteristic Control Intervention
Individual follow-up Group follow-up
N 221 (51) 216 (49)
Age (years) 41.5 (11.4) 40.1 (12.0)
Gender
Male 127 (57.5%) 108 (50%)
Female 94 (42.5%) 108 (50%)
Marital status
Married/cohabiting 106 (59.6%) 130 (65%)
Other 72 (40.4%) 70 (35%)
Education status
Completed 3rd level 96 (55.2%) 82 (41.6%)
Other 78 (44.8%) 115 (58.4%)
Employment status
Employed 136 (76.4%) 141 (70.1%)
Retired 6 (3.4%) 5 (2.5%)
Other 36 (20.2%) 55 (27.5%)
Years since diagnosis 16.3 (11.2) 15.5 (10.4)
Baseline BMI (kg/m2) 26.3 (4.3) 25.8 (4.0)
Baseline HbA1c (%) 8.2 (1.3) 8.4 (1.4)
Baseline HbA1c (mmol/mol) 66 (9.1) 68 (9.8)
Smoking status
Smoker 37 (20.6%) 42 (20.8%)
Non-smoker 143 (79.4%) 160 (79.2%)
Comorbidity status 75 (43%) 64 (33%)
Selected comorbidity status
Heart disease 4 (2%) 8 (4%)
High blood pressure 32 (18%) 10 (5%)
Chest/lung disease 3 (2%) 9 (5%)
Values are shown as mean (SD) or n (%) as appropriate. BMI, body mass index;
HbA1c, glycated haemoglobin. Data from Dinneen and colleagues [4].
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the analysis was addressed by estimating 95% CIs and cost
effectiveness acceptability curves (CEACs), which link the
probability of treatment being cost effective to a range of
potential threshold values (λ) that a health system may be
willing to pay per additional QALY gained [14]. The
CEACs were estimated using a two-stage bootstrapping
technique [13], which jointly accounts for the clustering
and correlation in the cost and effect data. In addition, a
series of sensitivity analysis was conducted. All analysis
was undertaken in the Stata 13 statistical software package
(StataCorp LP, USA).
Cost analysis
Two cost components were included in the analysis, all
of which were expressed in Euros (€) at 2009 prices. Thefirst related to the cost of implementing the group
follow-up intervention in clinical practice. This included
a range of resources such as educator and administrator
time input, educational materials and consumables,
post, packaging, telephone and travel expenses. This
data was recorded prospectively by the study research
team. The total cost of implementing the group follow-up
intervention was €39,933, giving a mean cost per par-
ticipant estimate of €185. This cost was allocated to
all patients in the group follow-up arm.
Second, costs relating to the use of primary and
secondary healthcare services over the course of the trial
were estimated for patients in both treatment arms. This
included the costs of general practitioner, dietitian, and
chiropodist consultations, diabetes day care centre,
outpatient, and accident and emergency visits, hospital
admissions, medications including insulin, lipid lowering,
antiplatelet, and antihypertensive therapies, and blood
glucose self-monitoring tests. Resource use was captured
via structured questionnaires completed by patients at
baseline and the three follow-up data collection points:
6, 12 and 18 months. A vector of unit costs was applied to
calculate the cost associated with each resource activity at
each time point. Notably, the baseline time point included
the period during which the DAFNE programme was
delivered. Unit cost estimates for each activity were
based on national data sources and, where necessary,
were transformed to Euros (€) at 2009 prices using appro-
priate indices [15] (see Table 3). In sensitivity analysis, the
effects of deflating the unit cost inputs by 10% and 50%
were examined.
For the purposes of the incremental analysis, a total
healthcare cost at 18 months follow-up variable was
constructed. The cost per individual resource activity at
18 months follow-up was calculated by aggregating
individual resource costs across the three follow-up
periods: 0 to 6 months, 6 to 12 months, and 12 to
18 months. The individual resource costs were then
summed to compute the total healthcare cost variable. To
facilitate this process, multiple imputation [12] was
undertaken using the MI package in Stata 13 to estimate
missing values for individual resource use cost data at
each time point. The imputation models for each variable
included age, gender, length of illness, treatment arm, and
hospital clinic, were estimated using predictive mean
matching, and were based on M = 5 imputed data sets.
Estimation of incremental total healthcare cost was
undertaken using a linear mixed effects regression model.
The model was estimated controlling for treatment arm,
baseline cost, age, gender, length of illness, HBA1c, body
mass index, heart disease status, high blood pressure
status, chest or lung disease status, smoking status,
medical card status, marital status, education status,
employment status, and clustering. The analysis was
Table 3 Categories of resource use and unit cost
estimates in 2009 (€) prices
Healthcare resource item Activity Unit
cost (€)
Source
GP clinic Per visit 50 ORC
Hospital admission Per inpatient day 832 DOHC
Outpatient clinic Per visit 169 DOHC
Accident and emergency clinic Per visit 289 DOHC
Diabetes nurse Per consultation 27 HSE
Dietitian Per consultation 24 HSE
Chiropodist Per consultation 24 HSE
Diabetes centre clinic Per visit 169 DOHC
Quick-acting insulin Per IU 0.02 MIMS
Background insulin Per IU 0.03 MIMS
Blood glucose monitoring Per test 0.39 NICE
Lipid lowering therapy Per day 1.33 MIMS
Antiplatelet therapy Per day 0.56 MIMS
Antihypertensive therapy Per day 0.74 MIMS
CSO, Central Statistics Office, Dublin, Ireland; DOF, Department of Finance,
Dublin, Ireland; DOHC, Casemix Unit, Department of Health and Children,
Dublin, Ireland; GP, general practitioner; HSE, Salary Scales, Health Service
Executive, Dublin, Ireland; IU, insulin unit; MIMS, Monthly Index of Medical
Specialties Ireland, Dublin, Ireland; NICE, National Institute of Clinical
Excellence, London, United Kingdom; ORC, Office of the Revenue
Commissioner, Dublin, Ireland.
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commands in Stata 13, which estimate the regression
model on each of the imputed data sets and apply Rubin’s
rules to generate the coefficients of interest [16]. To
account for the hierarchical and distributional nature
of the total cost variable, the regression models were
estimated with an exchangeable correlation structure
and with robust standards.
The adoption of two alternative model specifications
for the cost analysis was examined in sensitivity analysis.
First, a parsimonious model, controlling for treatment
arm, baseline cost, and clustering was estimated. Second,
a generalised linear model with cluster standard errors,
assuming a Gamma variance function and identity link
function, was estimated on the full set of covariates and
factors. Notably, multilevel models based on the Gamma
distribution may fit cost data better than Gaussian based
approaches [17]. We report findings from both approaches
for comparison.
Effectiveness analysis
Health outcomes in the analysis were expressed in terms
of QALYs gained, calculated using the EuroQol EQ5D 3
L instrument [18,19], a standardised tool designed to
describe and value health status. The EQ5D 3 L consists
of five dimensions: mobility, self-care, usual activities,
pain or discomfort and anxiety or depression; and each
dimension has three levels of severity: no problems,moderate problems or extreme problems. A scoring
algorithm is applied to transform EQ5D responses into a
single health state index score, which typically range
from 0 (equivalent to death) to 1 (equivalent to good
health), although a small number of health states are
valued as worse than death. The scoring algorithm is
based on values elicited via a time trade-off approach
for the UK population [20,21]. Quality-adjusted life
expectancy over a period of time is calculated by
weighting each component of the time period by its
relevant health state index score, using the area under
the curve method [22].
For the purposes of the incremental analysis, a 'QALYs
gained at 18 months' variable was constructed using the
EQ5D scores for each participant at baseline, 6, 12, and
18 months using the area under the curve method. Once
again, to facilitate this process, multiple imputation was
undertaken using the MI package in Stata 13 to estimate
missing values for EQ5D scores at each time point. The
imputation models for each variable included age, gender,
length of illness, treatment arm, and hospital clinic,
were estimated using predictive mean matching, and
were based on M = 5 imputed data sets.
Estimation of incremental QALYs gained was undertaken
using a linear mixed effects model. The model was
estimated controlling for treatment arm, baseline EQ5D
score, age, gender, length of illness, HBA1c, body mass
index, heart disease status, high blood pressure status,
chest or lung disease status, smoking status, medical card
status, marital status, education status, employment sta-
tus, and clustering. As for the cost analysis, the analysis
was undertaken using the MI estimate mixed and MI
predict commands in Stata 13.
In sensitivity analysis, a parsimonious model, controlling
for treatment arm, baseline EQ5D score, and clustering,
was estimated.
Cost effectiveness analysis
In economic evaluation, a treatment can be defined as
more cost effective than a comparator if one of the
following conditions apply: (a) it is less costly and more
effective; (b) it is more costly and more effective, but its
additional cost per additional unit of effect, known as
the incremental cost effectiveness ratio, is considered
worth paying by decision makers; or (c) it is less costly
and less effective, but the additional cost per additional
unit of effect of its comparator is not considered
worth paying by decision makers [6]. To identify
which scenario applies in any case, the incremental
estimates for the differences in mean cost and effect-
iveness between the treatment alternatives must be
examined.
To undertake cost effectiveness analysis alongside
cluster RCTs, techniques which recognise the clustering
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adopted [9]. In this case, separate multilevel regression
models, controlling for treatment arm, clustering, and a
range of other covariates and factors [11], were used to
estimate the incremental mean costs and QALYs for
group follow-up relative to individual follow-up. The
uncertainty surrounding these point estimates was
examined using a two-stage non-parametric bootstrapping
technique estimated using the TSB command in Stata
13 [13]. This method explicitly accounts for the correlation
and clustering in the hierarchical cost and effect data.
The results are presented using CEACs, which report
cost effectiveness probabilities for a range of potential
threshold values. In doing so, the CEACs incorporate
both the sampling uncertainty around the mean cost
effectiveness estimates and the uncertainty around the
cost effectiveness threshold value, [14], which is unknown
for Ireland [23].
Results
Raw data estimates for resource use and EQ5D scores at
baseline and each follow-up time point are presented in
Table 4. The equivalent unadjusted estimates for resource
costs and QALYs gained are summarised in Table 5.
Details on missing data at each time point are presented
in Additional file 1: Table S2.
The results from the incremental cost effectiveness
analysis are presented in Table 6. These indicate that
group follow-up was, on average, less costly and less
effective than individual follow-up. With respect to total
healthcare costs at 18 months, the mean cost per patient
estimates were €4,337 for the individual follow-up arm
and €3,551 for the group follow-up arm. The results from
the multilevel regression analysis indicate that group
follow-up was associated with a reduction in mean cost of
€772 (P value, 0.020; 95% CI, −1,415 to −128; ICC, 0.016)
per patient. In terms of QALYs gained at 18 months, the
mean estimates were 1.35 for individual follow-up and
1.31 for group follow-up. The multilevel regression results
indicate that group follow-up was associated with a reduc-
tion in mean QALYs of 0.04 (P value, 0.052; 95% CI, −0.08
to 0.01; ICC, 0.033) per patient.
The expected cost effectiveness results are summarised
in Table 6 and in Figure 1. At alternative threshold
values of €5,000, €15,000, €25,000, €35,000, and €45,000,
the probability of group follow-up being cost effective
was estimated to be 1.000, 0.762, 0.204, 0.078, and 0.033,
respectively.
The results from a series of sensitivity analysis are
presented in Additional file 1: Tables S3-S7. The results
from these analyses broadly reflect those from the
base-case analysis, with group follow-up consistently
estimated to be less costly and less effective than individ-
ual follow-up.Discussion
On the basis of evidence collected alongside a cluster
RCT, group follow-up care after the DAFNE programme
for type 1 diabetes was, on average, less effective and less
costly than standard one-to-one individual follow-up
care. These results supplement those from a parallel
clinical effectiveness study which reported that group
follow-up had no significant effect on the primary outcome
of HbA1c [4]. Here, we report that group follow-up did not
affect quality-adjusted life expectancy at 18 months.
Indeed, the QALYs gained outcomes were marginally
superior in the individual follow-up arm, although this did
not reach statistical significance in the base-case analysis.
Taken together, there appears to be no evidence that group
follow-up, as trialed in this study, would be a superior
strategy post-DAFNE for type 1 diabetes. With respect to
costs, group follow-up was associated with a statistically
significant saving of €772 per patient, when compared
to individual follow-up. Notably, the additional cost of
implementing group follow-up was offset by reductions
arising from differing patterns of resource use across
treatment arms over the course of the trial. This finding
suggests that, while group follow-up had no effect on
health outcomes, it did have important implications
for health service usage and costs of care. Indeed,
future studies should explore the cost effectiveness of
alternative models of group-based care for this patient
cohort.
In terms of the overall cost effectiveness findings, the
results for the group follow-up intervention lie in the
south west quadrant of the cost effectiveness plane; that
is, the intervention is less costly but less effective than
the control. In this quadrant, the intervention will be
considered cost effective if the amount saved is above
the threshold value, λ, per QALY gained [24]. In this
case, the results indicate a high probability of the group
follow-up intervention being cost effective at low levels
of λ but that this declines rapidly as λ increases beyond
€10,000. That is, the cost savings associated with group
follow-up are significant and are the main driver of cost
effectiveness for a range of low threshold values. However,
these costs savings are not sufficient to justify cost
effectiveness at higher threshold values, where greater
weight is placed on improved health outcomes. This
is observed graphically in the shape of the CEAC for
group follow-up in Figure 1, in that the CEAC cuts
the y-axis at a probability of 1.000 and declines
sharply as λ increases as the cost savings fall further
below the threshold value. The determination of cost
effectiveness in this case, therefore, is highly dependent on
the threshold value. Unfortunately, the lack of a formal
threshold value per QALY gained in Ireland only adds to
the uncertainty in the analysis [23]. This notwithstanding,
it is unlikely that decision makers in Ireland would
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GP visits: diabetes 0.50 (1.35) 0.37 (0.93) 0.25 (0.75) 0.17 (0.61) 0.28 (0.72) 0.15 (0.46) 0.25 (0.84) 0.28 (0.91)
GP visits: other 1.35 (1.95) 1.16 (1.72) 1.45 (2.44) 1.12 (1.43) 1.25 (1.61) 1.11 (1.37) 1.19 (2.06) 1.15 (1.42)
Diabetes nurse visits 1.09 (1.03) 0.90 (1.05) 0.72 (1.21) 0.58 (0.76) 0.57 (1.10) 0.43 (0.74) 0.45 (0.70) 0.46 (0.81)
Diabetes nurse calls 0.78 (1.78) 0.61 (1.78) 0.75 (1.42) 0.56 (1.06) 0.51 (1.26) 0.49 (1.06) 0.55 (1.22) 0.44 (1.36)
Dietitian visits 0.39 (0.59) 0.34 (0.74) 0.30 (0.60) 0.28 (0.53) 0.29 (0.67) 0.20 (0.44) 0.16 (0.38) 0.10(0.35)
Dietitian calls 0.05 (0.21) 0.04 (0.21) 0.28 (1.09) 0.10 (0.37) 0.12 (0.46) 0.10 (0.49) 0.05 (0.25) 0.06 (0.55)
Outpatient visits: diabetes 0.84 (0.76) 0.82 (0.65) 0.50 (0.59) 0.36 (0.58) 0.50 (0.60) 0.30 (0.53) 0.49 (0.61) 0.41 (0.62)
Outpatient visits: other 0.29 (0.72) 0.39 (1.55) 0.45 (1.67) 0.33 (0.88) 0.49 (1.29) 0.32 (0.80) 0.43 (0.94) 0.49 (1.17)
Inpatient days: diabetes 0.27 (1.44) 0.17 (0.86) 0.16 (0.95) 0.02 (0.19) 0.04 (0.30) 0.03 (0.16) 0.06 (0.44) 0.11 (0.64)
Inpatient days: other 0.24 (1.03) 0.39 (2.30) 0.29 (1.48) 0.10 (0.42) 0.46 (2.16) 0.22 (1.03) 0.19 (1.06) 0.15 (0.71)
A&E visits: diabetes 0.08 (0.36) 0.06 (0.26) 0.04 (0.18) 0.02 (0.19) 0.01 (0.08) 0.04 (0.20) 0.03 (0.16) 0.03 (0.16)
A&E visits: other 0.07 (0.27) 0.10 (0.36) 0.07 (0.28) 0.14 (0.48) 0.09 (0.33) 0.11 (0.42) 0.06 (0.24) 0.10 (0.35)
Chiropodist visits 0.27 (0.56) 0.25 (0.61) 0.32 (0.62) 0.20 (0.42) 0.31 (0.62) 0.23 (0.56) 0.32 (0.69) 0.23 (0.57)
Diabetes centre visits 1.35 (1.10) 1.25 (1.15) 1.02 (1.33) 0.80 (0.02) 0.92 (1.20) 0.70 (0.90) 0.79 (1.07) 0.72 (0.92)
Quick-acting insulin (IUs) 30.53 (15.15) 27.88 (14.56) 25.39 (13.73) 24.09 (13.57) 26.84 (12.82) 24.09 (15.12) 25.82 (13.14) 25.78 (13.69)
Background insulin (IUs) 25.68 (11.61) 24.35 (14.17) 21.11 (8.94) 19.02 (9.77) 21.44 (9.76) 19.22 (9.46) 21.80 (10.58) 20.39 (11.53)
Blood glucose tests 3.79 (2.38) 3.72 (1.99) 4.46 (1.91) 4.07 (1.43) 4.53 (1.96) 4.37 (1.93) 4.60 (2.04) 4.22 (2.04)
Lipid lowering therapy 67 (30%) 69 (32%) 46 (32%) 53 (36%) 49 (34%) 55 (34%) 48 (33%) 50 (37%)
Antiplatelet therapy 53 (24%) 70 (32%) 43 (30%) 51 (35%) 43 (30%) 54 (33%) 40 (27%) 45 (33%)
Antihypertensive therapy 57 (26%) 76 (35%) 28 (20%) 51 (35%) 32 (22%) 51 (35%) 30 (21%) 49 (36%)
Health outcome
EQ5D score 0.88 (0.20) 0.87 (0.18) 0.91 (0.15) 0.88 (0.16) 0.92 (0.14) 0.86 (0.20) 0.90 (0.16) 0.88 (0.17)
Values are shown as mean (SD) or n (%) as appropriate. A&E, accident and emergency; EQ5D, EuroQol five dimensions; GP, general practitioner; IU, insulin unit.
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lack of clinical benefit.
This study adds to the limited literature on the cost
effectiveness of complex group-based interventions
which seek to improve self-management in patients with
type 1 diabetes. A study by Trento and colleagues [25]
reported on a 3-year RCT of group care compared to
one-to-one clinic visits for individuals with type 1 diabetes.
The study randomised 62 patients and delivered 15 group
care sessions over 3 years. They reported improvement in
knowledge, health behaviours and quality of life and a
marginal increase in costs, but no change in HbA1c. While
a full economic evaluation was not undertaken, the authors
concluded that group care was cost effective. Notably, the
relatively longer follow-up period in the trial by Trento
and colleagues [25] may be an important indicator of why
they found improvements in health outcomes and we did
not. A second study by Ismail and colleagues [26] reported
that group-based motivational enhancement therapy and
cognitive behavioural therapy led to an improvement inHbA1c levels at 12 months for individuals with poorly
controlled type 1 diabetes. However, the benefits were not
observed at 4 years follow-up, thereby indicating that
some form of ongoing intervention may be required
[27]. Moreover, the economic evaluation at 12 months
proved inconclusive [28]. These findings, along with
our results, can only add to the outstanding question
of how health outcomes for type 1 diabetes, which is
a young high-risk population, can be improved.
From an Irish perspective, where the traditional
approach to chronic disease management in the
community may be described as reactive in nature, our
findings highlight the potential resource implications of
adopting a more proactive and systematic approach to
care. This is particularly relevant given future projections
of a growing number of people with chronic disease in
Ireland [29], and concerns over the ability of an already
resource-constrained healthcare infrastructure to cope
with the expected increase in need. Notably, the observed
resource usage patterns in this study appear to be true for
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GP visits: diabetes 25 (68) 19 (46) 12 (38) 9 (30) 14 (36) 7 (23) 13 (42) 14 (45)
GP visits: other 68 (98) 58 (86) 73 (122) 56 (72) 62 (81) 56 (69) 59 (103) 58 (71)
Diabetes nurse visits 29 (28) 24 (28) 20 (33) 16 (21) 16 (30) 12 (20) 12 (19) 12 (22)
Diabetes nurse calls 21 (48) 17 (48) 20 (38) 15 (29) 14 (34) 13 (29) 15 (33) 12 (37)
Dietitian visits 9 (14) 8 (18) 7 (15) 7 (13) 7 (16) 5 (11) 4 (9) 3 (8)
Dietitian calls 1 (5) 1 (5) 7 (26) 2 (8) 3 (11) 2 (12) 1 (6) 2 (13)
Outpatient visits: diabetes 143 (128) 139 (110) 85 (99) 60 (98) 85 (101) 50 (89) 83 (103) 69 (104)
Outpatient visits: other 49 (122) 66 (262) 76 (282) 55 (149) 83 (218) 54 (134) 72 (158) 83 (198)
Inpatient days: diabetes 228 (1199) 139 (716) 131 (792) 19 (160) 33 (251) 21 (129) 50 (362) 90 (533)
Inpatient days: other 195 (860) 324 (1913) 242 (1230) 80 (350) 383 (1799) 184 (853) 161 (882) 124 (593)
A & E visits: diabetes 23 (104) 17 (74) 10 (53) 6 (56) 2 (23) 12 (58) 8 (47) 8 (47)
A & E visits: other 20 (79) 30 (105) 20 (80) 41 (138) 26 (96) 31 (122) 17 (69) 29 (100)
Chiropodist visits 7 (13) 6 (15) 8 (15) 5 (10) 8 (15) 6 (13) 8 (17) 6 (14)
Diabetes centre visits 229 (187) 211 (194) 172 (225) 136 (156) 156 (203) 118 (153) 133 (180) 122 (156)
Quick-acting insulin 111 (55) 102 (53) 93 (50) 88 (50) 98 (47) 88 (55) 94 (48) 94 (50)
Background insulin 94 (42) 89 (52) 77 (33) 69 (36) 78 (36) 70 (35) 80 (39) 74 (42)
Blood glucose tests 270 (169) 265 (141) 317 (136) 290 (102) 323 (139) 311 (137) 327 (145) 301 (145)
Lipid lowering therapy 76 (113) 79 (114) 78 (114) 87 (117) 82 (115) 89 (117) 80 (115) 89 (117)
Antiplatelet therapy 26 (44) 34 (48) 31 (47) 36 (49) 30 (47) 36 (49) 28 (47) 33 (48)
Antihypertensive therapy 36 (60) 49 (65) 26 (54) 49 (65) 30 (56) 47 (64) 28 (55) 49 (65)
Total cost
Total healthcare cost 1,597 (1,549) 1,643 (2,416) 1,413 (1,347) 1,189 (840) 1,343 (1588) 1,246 (1021) 1,274 (1181) 1,283 (1105)
Health outcome
QALYs gained 0.44 (0.09) 0.43 (0.09) 0.45 (0.08) 0.44 (0.07) 0.46 (0.05) 0.43 (0.07) 0.46 (0.06) 0.44 (0.08)
Values are shown as mean (SD) or n (%) as appropriate. A&E, accident and emergency; GP, general practitioner; QALY, quality-adjusted life year.
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heart disease. For example, a recent Irish RCT evaluated
group-based peer support sessions to supplement formal
healthcare support for individuals with type 2 diabetes in
Irish general practice [30]. While the clinical study showed
no significant difference in terms of HbA1c, group-based
peer support was shown to be cost saving relative to usual
care. A second Irish RCT evaluating primary care clinics
for the secondary prevention of coronary heart disease in
Irish general practice reported significant reductions in
hospital admissions and costs of care relative to usual
care [31,32]. While further evidence is required, these
results suggest a tentative pattern of beneficial resource
implications from more proactive approaches to chronic
disease management in the community.
There were a number of limitations in this study.
Participants were randomised to control and interventionfollowing the collection of baseline data, which indicate
that both groups were well matched [4]. However, there
was no feasible way to blind the intervention group to
participants or to those facilitating the programme
and the study is open to a risk of performance bias.
Nevertheless, outcome assessment was blinded thus mini-
mising risks to detection bias. As data were collected via
structured questionnaires, there are important concerns
with respect to participant recall bias at each data
collection point. In an attempt to minimise, although
admittedly not eradicate, this issue, follow-up data
were collected at three consecutive 6-month intervals.
With respect to health outcomes, given the lack of
Irish utility data for the EQ5D 3 L instrument, the
equivalent UK algorithm was adopted and assumed to
be generalisable to the Irish population with type 1
diabetes. This may not be the case and reflects the
Table 6 Incremental cost effectiveness analysis results






Total healthcare cost (€)
Mean (SD) 3,551 (566) 4,337 (551) 0.016
Incremental analysis (difference in means; intervention versus control) −772 (95% CI, −1,415 to −128; P = 0.020)
Effectiveness analysis
QALYs gained
Mean (SD) 1.31 (0.12) 1.35 (0.12) 0.033
Incremental analysis (difference in means; intervention versus control)
−0.04 (95% CI, −0.08 to 0.01; P = 0.052)
Cost effectiveness analysis (probability that treatment is
cost effective at λ
Threshold value (λ)
λ = €0 1.000 0.000
λ = €5,000 1.000 0.000
λ = €10,000 0.996 0.004
λ = €15,000 0.762 0.238
λ = €20,000 0.400 0.600
λ = €25,000 0.204 0.796
λ = €30,000 0.119 0.881
λ = €35,000 0.078 0.922
λ = €40,000 0.049 0.951
λ = €45,000 0.033 0.967
λ or threshold value of the maximum that the health system would be willing to pay per QALY gained. ICC, intra-class coefficient; QALY, quality-adjusted life year.
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evaluation in Ireland.
While the cost analysis was conducted from the health
service perspective and included a broad range of resource
use activities, certain resource items were not captured; for
example, the costs of diabetes eye screening were not
included. Furthermore, private patient costs such as private
health insurance premiums, and broader costs to society
such as productivity losses were not captured in the ana-
lysis. Nonetheless, there is little to suggest that the inclu-
sion of these resource categories would fundamentally
change the results as presented. The process of conducting
cost analysis in Ireland is also compromised by the lack of
nationally available unit cost data. In estimating unit costs
for individual resource activities, we endeavoured at all
times to be conservative in any assumptions adopted. It
should also be noted that we adopt 2009 prices for the ana-
lysis and medical inflation has fallen in the period since the
trial was conducted. To examine the uncertainty surround-
ing the unit cost estimates, sensitivity analysis was con-
ducted in which unit cost data were deflated by 10% and
50%, respectively. Neither set of results fundamentally
differed from those of the base-case analysis.We employed appropriate methods for the statistical
analysis of cost and effect data collected alongside
cluster RCTs. Notably, clustering for the variables of
interest was moderate, with ICCs of 0.016 for total
healthcare cost and 0.033 for QALYs gained. Moreover,
the correlation coefficient for costs and QALYs gained
was −0.18. To account for potential covariate imbalances
between treatment arms at baseline [11], we estimated
separate linear mixed effects multilevel regression
models for costs and QALYs, controlling for a range of
covariates and factors. To jointly account for correlation
and clustering, we adopted a two-stage non-parametric
bootstrapping technique [10]. While the methods adopted
were appropriate, arguments could be made for a number
of alternative approaches. For example, the adopted linear
mixed effects model may be problematic in cases
where the distribution of the data deviates significantly
from normality. As referenced above, the statistical
analysis of cost data is often one such case. That said,
the application of more flexible approaches such as
generalised estimating equations is problematic when,
such as in this study, the number of clusters is small
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Figure 1 Cost effectiveness acceptability curves for group follow up and individual follow up.
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for the cost analysis estimated using a generalised linear
model assuming a Gamma distribution did not differ
fundamentally from the base-case analysis. This was also
true for the parsimonious analysis, which explored the
impact of varying the independent variables in the cost
and QALYs regressions models.
As noted above, data were collected via structured
questionnaires and, consequently, missing data was an
important consideration in the analysis. Details on missing
data at each data collection point are presented in
Additional file 1: Table S7. After careful consideration
of missing data patterns, we proceeded with the assump-
tion that the data were missing at random and multiple
imputation was undertaken to impute missing values using
the MI command in Stata 13. The variables included in the
imputation models were pragmatically chosen by the study
team and included age, gender, length of illness, treatment
arm, and study centre. This approach may be criticised on
the basis that values for resource use and EQ5D scores
were imputed independently. Furthermore, hospital clinic
was included as a fixed effect in the imputation model,
reflecting recent guidance that the imputation model
should be compatible with the analysis model: that is, both
should reflect the multilevel nature of the data [13]. The
approach of including the cluster variable as a fixed effect
in the imputation model may be problematic in some cases
[33]; however, given the small number of clusters in the
trial, we deemed it to be appropriate. Indeed, given the
moderate ICCs observed, we examined the impact of
excluding the cluster effect from the imputation
models in sensitivity analyses. Notably, the results
were generally consistent with the base-case analysis,
although the difference in QALYs gained between
group follow-up and individual follow-up became
statistically significant. This goes to highlight theimportance of applying multilevel imputation models
in such cases.
Finally, in the case of chronic disease, a lifetime horizon
for analysis is encouraged as interventions may have
long-terms implications which occur beyond the end
of trial follow-up [6]. Given the absence of improvement
in clinical outcomes at 18 months, modelling approaches
were not considered in this case and the time horizon of
analysis was limited to trial follow-up. Nonetheless,
additional follow-up of patients in the trial is essential to
explore whether longer term events have a substantive
effect on the results presented here.
Conclusion
There is little evidence to support the implementation of
group care as the sole means of follow-up after structured
education for individuals with type 1 diabetes. Nonetheless,
given the reported cost savings, as well as the growing
budget constraints facing health systems worldwide, future
studies should continue to explore the clinical and cost ef-
fectiveness of alternative models of group care for diabetes.Additional file
Additional file 1: Table S1. Comparison of HbA1c between
Intervention and Control arms at Baseline and Follow-up. Table S2.
Completeness of Data at Baseline and Follow Up Time Points. Table S3.
Sensitivity Analysis 1: Parsimonious Regression Model Results: (1) Incremental
Costs estimated controlling for Arm, Baseline Costs and Clustering; (2)
Incremental QALYs estimated controlling for Arm, Baseline EQ5D Score and
Clustering. Table S4. Sensitivity Analysis 2: Alternative Regression Model
Specification for the Incremental Cost Analysis: GLM regression model,
assuming a GAMMA Variance function, an identity Link Function, and
clustered standard errors. Table S5. Sensitivity Analysis 3: Assuming that unit
costs in Ireland are 10% less than those adopted in the Base-Case Analysis.
Table S6. Sensitivity Analysis 4: Assuming that unit costs in Ireland are 50%
less than those adopted in the Base-Case Analysis. Table S7. Alternative
Imputation Model Specification Results: Single Level Imputation.
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